>> AVI licensed its vascular disease program to the Cook Group Inc. (Cook) in March 2006 for device delivery of the NeuGene® antisense drug AVI–4126, while the company is focusing internal development on coronary artery bypass graft (CABG) using AVI–5126. <<
>By the way, what ever happened to Resten-NG?<
An entire chapter in the book Biotech Fiascos will be devoted to answering this. (Just kidding.) I would give the details, but I am suffering from PTASD (Post-Traumatic AVII-Shareholder Disorder.)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.